Drug intelligence / Profile preview

NM57S + NC08

Development stage: Unknown
Lead developer: North China Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intramuscular

Overview

NM57S + NC08 is a combination of two monoclonal antibodies developed as a rabies virus neutralization therapy. The drug acts as an inhibitor of the rabies virus glycoprotein (RABV-G), thereby neutralizing the rabies virus and preventing infection. It was initially developed by North China Pharmaceutical Co., Ltd., with clinical development conducted by its subsidiary, NCPC New Drug Research & Development Co. Ltd. The primary indication is for post-exposure prophylaxis or treatment of rabies in humans. Clinical trials have evaluated its safety, tolerability, pharmacokinetics, neutralizing antibody activity, and immunogenicity in healthy volunteers[1][3][8].

Other names: NM57S/NC08NM-57S/NC-08

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on NM57S + NC08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NM57S + NC08.

Explore the full profile